Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing

BACKGROUND AND OBJECTIVES: REC-2282 is a novel histone deacetylase inhibitor that has shown antitumor activity in in vitro and in vivo models of malignancy.  The aims of this study were to characterize the population pharmacokinetics of REC-2282 (AR-42) from the first-in-human (NCT01129193) and phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Liva, Sophia, Chen, Min, Mortazavi, Amir, Walker, Alison, Wang, Jiang, Dittmar, Kristin, Hofmeister, Craig, Coss, Christopher C., Phelps, Mitch A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599380/
https://www.ncbi.nlm.nih.gov/pubmed/34618345
http://dx.doi.org/10.1007/s13318-021-00722-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599380/
https://www.ncbi.nlm.nih.gov/pubmed/34618345
http://dx.doi.org/10.1007/s13318-021-00722-z

Ejemplares similares